Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status.
AffiliationAuthors' Affiliations: Molecular Pathology, Breakthrough Breast Cancer, School of Cancer, Paterson Institute for Cancer Research, University of Manchester, UK; Wellcome Trust Centre for Cell-Matrix Research, Michael Smith Building, Faculty of Life Sciences, University of Manchester, UK; Breast Biology, School of Cancer, Paterson Institute for Cancer Research, University of Manchester, UK; Sahlgrenska Cancer Center, Institute of Biomedicine, 405 30 Göteborg, Sweden.
MetadataShow full item record
AbstractTumor hypoxia is often linked to decreased survival in patients with breast cancer and current therapeutic strategies aim to target the hypoxic response. One way in which this is done is by blocking hypoxia-induced angiogenesis. Antiangiogenic therapies show some therapeutic potential with increased disease-free survival, but these initial promising results are short lived and followed by tumor progression. We hypothesized that this may be due to altered cancer stem cell (CSC) activity resulting from increased tumor hypoxia. We studied the effects of hypoxia on CSC activity, using in vitro mammosphere and holoclone assays as well as in vivo limiting dilution experiments, in 13 patient-derived samples and four cell lines. There was a HIF-1α-dependent CSC increase in ER-α-positive cancers following hypoxic exposure, which was blocked by inhibition of estrogen and Notch signaling. A contrasting decrease in CSC was seen in ER-α-negative cancers. We next developed a xenograft model of cell lines and patient-derived samples to assess the hypoxic CSC response. Varying sizes of xenografts were collected and analyzed for HIF1-α expression and CSC. The same ER-α-dependent contrasting hypoxic-CSC response was seen validating the initial observation. These data suggest that ER-α-positive and negative breast cancer subtypes respond differently to hypoxia and, as a consequence, antiangiogenic therapies will not be suitable for both subgroups. Cancer Res; 73(4); 1420-33. ©2012 AACR.
CitationContrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status. 2013, 73 (4):1420-33 Cancer Res
- Distinct breast cancer stem/progenitor cell populations require either HIF1α or loss of PHD3 to expand under hypoxic conditions.
- Authors: Iriondo O, Rábano M, Domenici G, Carlevaris O, López-Ruiz JA, Zabalza I, Berra E, Vivanco Md
- Issue date: 2015 Oct 13
- Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.
- Authors: Padró M, Louie RJ, Lananna BV, Krieg AJ, Timmerman LA, Chan DA
- Issue date: 2017 Mar 20
- Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.
- Authors: Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD, Cushing RC, Seagroves TN
- Issue date: 2012 Jan 7
- Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
- Authors: Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA
- Issue date: 2011 Apr 6
- Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.
- Authors: Syed Khaja AS, Dizeyi N, Kopparapu PK, Anagnostaki L, Härkönen P, Persson JL
- Issue date: 2013